OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innovus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.23 0.00 (0.00 %) (As of 02/14/2020) Add Compare Today's Range$1.11Now: $1.23▼$1.2350-Day Range$0.85MA: $1.02▼$1.2552-Week Range$0.75Now: $1.23▼$11.50Volume13,279 shsAverage Volume21,102 shsMarket Capitalization$3.94 millionP/E RatioN/ADividend YieldN/ABeta2.1 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:INNV Previous SymbolNASDAQ:INNV CUSIPN/A CIK1411879 Webhttp://www.innovuspharma.com/ Phone858-964-5123Debt Debt-to-Equity Ratio13.78 Current Ratio0.50 Quick Ratio0.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.99 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book24.60Profitability EPS (Most Recent Fiscal Year)($4.16) Net Income$-8,280,000.00 Net Margins-35.85% Return on Equity-1,611.96% Return on Assets-77.85%Miscellaneous Employees27 Outstanding Shares3,200,000Market Cap$3.94 million Next Earnings Date4/6/2020 (Estimated) OptionableNot Optionable Receive INNV News and Ratings via Email Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter. OTC:INNV Rates by TradingView Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions What is Innovus Pharmaceuticals' stock symbol? Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV." How were Innovus Pharmaceuticals' earnings last quarter? Innovus Pharmaceuticals Inc (OTCMKTS:INNV) issued its earnings results on Tuesday, August, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $7.31 million for the quarter. Innovus Pharmaceuticals had a negative net margin of 35.85% and a negative return on equity of 1,611.96%. View Innovus Pharmaceuticals' Earnings History. When is Innovus Pharmaceuticals' next earnings date? Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Innovus Pharmaceuticals. What price target have analysts set for INNV? 1 equities research analysts have issued twelve-month price objectives for Innovus Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Innovus Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 306.5% from the stock's current price. View Analyst Price Targets for Innovus Pharmaceuticals. What is the consensus analysts' recommendation for Innovus Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovus Pharmaceuticals. Has Innovus Pharmaceuticals been receiving favorable news coverage? Media stories about INNV stock have trended neutral recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innovus Pharmaceuticals earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Innovus Pharmaceuticals. Who are some of Innovus Pharmaceuticals' key competitors? Some companies that are related to Innovus Pharmaceuticals include Mateon Therapeutics (MATN), Heat Biologics (HTBX), Aytu Bioscience (AYTU), Novan (NOVN), Zosano Pharma (ZSAN), Conatus Pharmaceuticals (CNAT), IMMURON LTD/S (IMRN), Novelion Therapeutics (NVLN), Novelion Therapeutics (NVLNF), Diffusion Pharmaceuticals (DFFN), OTCMKTS:EMBI (EMBI), Nemus Bioscience (NMUS), KITOV PHARMA LT/S (KTOV), KemPharm (KMPH) and Acerus Pharmaceuticals (ASPCF). What other stocks do shareholders of Innovus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innovus Pharmaceuticals investors own include EEStor (ESU), Antares Pharma (ATRS), The Medicines (MDCO), Federal National Mortgage Association (FNMA), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), NVIDIA (NVDA), Pacific Premier Bancorp (PPBI) and Prospect Capital (PSEC). Who are Innovus Pharmaceuticals' key executives? Innovus Pharmaceuticals' management team includes the folowing people: Dr. Bassam B. Damaj, Pres, CEO & Director (Age 51)Mr. Ryan J. Selhorn CPA, VP & CFO (Age 37)Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 58)Mr. Christopher Stella, VP of OperationsMr. Robert C. Verfurth, VP of Sales & Marketing How do I buy shares of Innovus Pharmaceuticals? Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Innovus Pharmaceuticals' stock price today? One share of INNV stock can currently be purchased for approximately $1.23. How big of a company is Innovus Pharmaceuticals? Innovus Pharmaceuticals has a market capitalization of $3.94 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.View Additional Information About Innovus Pharmaceuticals. What is Innovus Pharmaceuticals' official website? The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com/. How can I contact Innovus Pharmaceuticals? Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected] MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 119 (Vote Outperform)Underperform Votes: 141 (Vote Underperform)Total Votes: 260MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe INNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2020 by MarketBeat.com StaffFeatured Article: What is the Consumer Price Index (CPI)?
